← board
NIKA
distress 4/10 · elevated risk$0.770%today-20% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
+2%
Price & events
+102.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+280.7%
1M
+5.4%
3M
+102.4%
6M
+11.4%
1Y
+50.8%
2Y
—
5Y
-94.5%
All
Overview
- Market Cap
- $806.33M
- Volume
- 0
- 52 Week Range
- $0.20 – $0.96
- Total Shares
- 1.05B
- Float Shares
- 275.78M
- % Held by Insiders
- 86.28%
- % Held by Institutions
- 0.00%
- Beta
- -2.48
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 1,048,549,224 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.